Should You Worry That a Natera Co-Founder Sold Shares? Here's What Long-Term Investors Should Know

Matthew Rabinowitz, the executive chairman of Natera, Inc. (NASDAQ:NTRA), sold 731 shares of common stock at $267.99 per share on August 3, according to an SEC Form 4 filing.

Transaction summary

Metric	Value
Shares sold (directly held)	731
Transaction value	$195,901
Post-transaction shares (directly held)	2,275,394
Post-transaction shares (indirectly held)	4,000
Post-transaction value	$616.26 million

Transaction value based on SEC Form 4 weighted average sale price ($267.99); post-transaction value based on the August 3 market close ($270.36).

Key questions

• What was the motivation for this disposition?
  The sale was non-discretionary and performed specifically to satisfy tax withholding and remittance obligations triggered by the vesting of restricted stock units. This arrangement was established under a Rule 10b5-1(c) plan dated January 31, 2025, and does not reflect a discretionary change in the executive's investment thesis.
• How significant is the remaining equity position?
  Matthew Rabinowitz continues to hold a substantial interest in the company, with roughly 2.3 million shares held directly and an additional 4,000 shares held indirectly through a spouse. This total beneficial ownership is valued at approximately $616.26 million as of the August 3 market close.
• What is the recent performance context for the stock?
  As of the August 3 transaction date, Natera had delivered a one-year total return of roughly 100%. The stock was priced at $275.19 as of the August 4 market close, representing a market capitalization of $39.4 billion.

Company Overview

Metric	Value
Share Price (as of market close 2026-08-04)	$275.19
Market Capitalization	$39.4 billion
Revenue (TTM)	$2.7 billion
Net Income (TTM)	-$192.3 million

Company Snapshot

• Natera develops and commercializes a comprehensive portfolio of molecular diagnostic testing services, including Panorama (non-invasive prenatal testing), Vistara (single-gene disorder screening), and Horizon (carrier screening), generating revenue through direct laboratory testing services and licensing arrangements.
• The company operates a laboratory services business model, processing patient samples and delivering diagnostic results to healthcare providers and patients, with revenue derived from test volumes, per-test pricing, and reimbursement from insurance carriers and government programs.
• Natera serves obstetricians, gynecologists, reproductive endocrinologists, and genetic counselors as primary customers, while targeting expectant parents and individuals seeking genetic risk assessment across prenatal, carrier, and hereditary cancer screening markets.

Natera is a leading molecular diagnostics company with a market capitalization of $39.4 billion and TTM revenue of $2.7 billion, positioning it among the largest players in the genetic testing sector. The company has achieved substantial scale and maintains a diversified test portfolio addressing multiple clinical indications across reproductive health and hereditary disease screening. Despite current net losses, Natera's strong revenue growth trajectory and commanding market position reflect investor confidence in the expanding demand for non-invasive genetic testing solutions.

What this transaction means for investors

Set against what he owns, this sale rounds to nothing. Rabinowitz sold 731 shares while holding roughly $616 million of Natera stock, so the fraction that left to cover a tax bill is a rounding error on a co-founder's fortune — which is a billionaire-level fortune in this case, according to Forbes. The shares vested and were withheld automatically under a plan set in early 2025, which is about as far from a discretionary call as an insider filing gets. He sold on August 3, days before the company reported, so the timing predates the news that moved the stock.

That report was a strong one. Natera grew second-quarter revenue about 38% to $753 million, beat expectations handily, and raised its full-year outlook, driven by its Signatera cancer test, whose clinical volume climbed 56%. Gross margin reached about 65%, up on better pricing and efficiency. So what’s the verdict for long-term investors? A co-founder parting with a few hundred shares to satisfy taxes, days before a quarter like that, really tells you nothing except that the calendar and the tax code did their usual work. More importantly, the firm is firing on all cylinders, and momentum is on its side.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Natera. The Motley Fool has a disclosure policy.